Treatment of Advanced Parkinson’s Disease in the United StatesA Cost-Utility Model

被引：0
|
作者：
Huybert Groenendaal
Marcy L. Tarrants
Christophe Armand
机构：
[1] Vose Consulting,
[2] Teva Neuroscience,undefined
[3] Inc.,undefined
[4] H. Lundbeck A/S,undefined
来源：
Clinical Drug Investigation | 2010年 / 30卷
关键词：
Levodopa; Direct Medical Cost; Rasagiline; Entacapone; Motor Fluctuation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: As Parkinson’s disease (PD) progresses, patients and their families experience substantial health and economic burdens. Because motor fluctuations (also called ‘off-time’) are linked to poor quality of life and higher healthcare costs, minimizing off-time is an effective strategy for reducing costs associated with PD.
引用
收藏
页码：789 / 798
页数：9
相关论文
共 50 条
  • [1] TREATMENT OF ADVANCED PARKINSON'S DISEASE IN THE UNITED STATES: A COST-UTILITY MODEL
    Tarrants, M. L.
    Groenendaal, H.
    Armand, C.
    VALUE IN HEALTH, 2009, 12 (07) : A370 - A370
  • [2] Treatment of Advanced Parkinson's Disease in the United States A Cost-Utility Model
    Groenendaal, Huybert
    Tarrants, Marcy L.
    Armand, Christophe
    CLINICAL DRUG INVESTIGATION, 2010, 30 (11) : 789 - 798
  • [3] Treatment of advanced Parkinson's disease in the United States: a cost-utility model
    Tarrants, M.
    Groenendaal, H.
    Armand, C.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S135 - S136
  • [4] Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland
    Hudry, J
    Rinne, JO
    Keränen, T
    Eckert, L
    Cochran, JM
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (04) : 651 - 657
  • [5] COST-UTILITY OF DEEP BRAIN STIMULATION FOR THE TREATMENT OF ADVANCED PARKINSON'S DISEASE IN THE UNITED STATES
    Pietzsch, J. B.
    Garner, A. M.
    Marks, W. J.
    VALUE IN HEALTH, 2015, 18 (03) : A43 - A43
  • [6] ADAPTATION OF A COST-UTILITY MODEL OF RASAGILINE IN THE TREATMENT OF PARKINSON'S DISEASE IN CHINA
    Chen, S.
    Chen, H.
    Zhang, B.
    Shang, H.
    Tan, K. H.
    Ma, F.
    Dorey, J.
    Le Lay, A.
    VALUE IN HEALTH, 2018, 21 : S94 - S94
  • [7] COST-UTILITY ANALYSIS OF ROPINIROLE IN PARKINSON'S DISEASE (PD) TREATMENT
    Zerda, I
    Drozdz, A.
    Brzyski, D.
    Pochopien, M.
    Gwiosda, B.
    Lisiecka, B.
    Barlog, D.
    Glogowski, C.
    Dziurda, D.
    Rys, P.
    Plisko, R.
    VALUE IN HEALTH, 2011, 14 (07) : A323 - A323
  • [8] Cost-Effectiveness and Cost-Utility of Early Levodopa in Parkinson's Disease
    Verschuur, Constant V. M.
    Suwijn, Sven R.
    de Haan, Rob J.
    Boel, Judith A.
    Post, Bart
    Bloem, Bas R.
    van Hilten, Johannes J.
    van Laar, Teus
    Tissingh, Gerrit
    Munts, Alexander
    Dijkgraaf, Marcel G. W.
    de Bie, Rob M. A.
    JOURNAL OF PARKINSONS DISEASE, 2022, 12 (07) : 2171 - 2178
  • [9] THE ROLE OF STRUCTURAL SENSITIVITY ANALYSIS IN THE MODELLING OF COST-EFFECTIVENESS (COST-UTILITY) IN PARKINSON'S DISEASE IN THE UNITED STATES AND UNITED KINGDOM
    Ratcliffe, A. E.
    VALUE IN HEALTH, 2012, 15 (04) : A145 - A145
  • [10] Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales
    Kalabina, Svetlana
    Belsey, Jonathan
    Pivonka, Dominic
    Mohamed, Biju
    Thomas, Chris
    Paterson, Brian
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (03) : 215 - 225
12345